
Ajax develops precise, best-in-class therapies for hematologic malignancies using advanced structural biology and computational chemistry.
Ajax Therapeutics, founded with a mission to revolutionize the treatment of hematologic malignancies, leverages advanced structural biology and computational chemistry to develop precise, best-in-class therapies. The company focuses on myeloproliferative neoplasms (MPNs) and aims to address significant unmet medical needs by creating targeted therapies that minimize interactions with non-target proteins, thereby enhancing efficacy and reducing side effects.
Notable figures associated with Ajax Therapeutics include experts in molecular genetics and structural biology, although specific names are not provided. The company has made significant strides in drug discovery and development, positioning itself as a leader in the field of hematologic cancer treatment. Its impact is marked by the potential to offer more effective and safer treatment options for patients suffering from MPNs and other hematologic malignancies.

Ajax Health
ajaxhealth.com

Adcentrx Therapeutics
adcentrx.com

Aether Therapeutics

Accent Therapeutics
accenttx.com

Athos Therapeutics
athostx.com

Akebia Therapeutics
akebia.com

Nine Square Therapeutics
ninesquaretx.com

ProFound Therapeutics
profoundtx.com

Axonis Therapeutics

Bluejay Therapeutics
bluejaytx.com

AimMax Therapeutics
aimmaxrx.com

Window Therapeutics
windowtx.com

Apexian Pharmaceuticals
apexianpharma.com

Nextrna Therapeutics

AsclepiX Therapeutics
asclepix.com
Companies similar to Ajax Therapeutics include Ajax Health, Adcentrx Therapeutics, Aether Therapeutics and Accent Therapeutics.
Ajax Therapeutics was founded in 2019.
Ajax Therapeutics' headquarters is located in New York City, NY, US.
Ajax Therapeutics' most recent funding round was for $40M (USD) in June 2021.
As of Jun 1, 2021, Ajax Therapeutics has raised a total of $40M (USD).
Ajax Therapeutics has 15 employees as of Feb 5, 2024.